BIOMAT Database Logo BIOMAT Database Logo

Clinical evaluation of hemostatic molecular markers. 1988

M Kazama

UI MeSH Term Description Entries
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D005344 Fibrinopeptide A Two small peptide chains removed from the N-terminal segment of the alpha chains of fibrinogen by the action of thrombin during the blood coagulation process. Each peptide chain contains 18 amino acid residues. In vivo, fibrinopeptide A is used as a marker to determine the rate of conversion of fibrinogen to fibrin by thrombin. Fibrinopeptides A
D006487 Hemostasis The process which spontaneously arrests the flow of BLOOD from vessels carrying blood under pressure. It is accomplished by contraction of the vessels, adhesion and aggregation of formed blood elements (eg. ERYTHROCYTE AGGREGATION), and the process of BLOOD COAGULATION. Hemostases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001620 beta-Thromboglobulin A platelet-specific protein which is released when platelets aggregate. Elevated plasma levels have been reported after deep venous thrombosis, pre-eclampsia, myocardial infarction with mural thrombosis, and myeloproliferative disorders. Measurement of beta-thromboglobulin in biological fluids by radioimmunoassay is used for the diagnosis and assessment of progress of thromboembolic disorders. beta-2 Thromboglobulin,Thromboglobulin, beta-2,beta 2 Thromboglobulin,beta Thromboglobulin
D013923 Thromboembolism Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. Thromboembolisms
D018179 Receptors, Thrombin A family of proteinase-activated receptors that are specific for THROMBIN. They are found primarily on PLATELETS and on ENDOTHELIAL CELLS. Activation of thrombin receptors occurs through the proteolytic action of THROMBIN, which cleaves the N-terminal peptide from the receptor to reveal a new N-terminal peptide that is a cryptic ligand for the receptor. The receptors signal through HETEROTRIMERIC GTP-BINDING PROTEINS. Small synthetic peptides that contain the unmasked N-terminal peptide sequence can also activate the receptor in the absence of proteolytic activity. Thrombin Receptors,TRAP Peptide,Thrombin Receptor,Thrombin Receptor Activating Peptide Ligand,Thrombin Receptor Activating Peptides,Thrombin Receptor Activator Peptide,Peptide, TRAP,Receptor, Thrombin

Related Publications

M Kazama
[Clinical significance of hemostatic molecular markers in acute leukemia].
March 2001, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
M Kazama
[Clinical study of hemostatic molecular markers expression in patients with cancer].
November 2004, Zhonghua nei ke za zhi,
M Kazama
[A clinical study on hemostatic fluctuation during and after cardiopulmonary bypass using hemostatic molecular markers].
November 1992, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
M Kazama
Hemostatic molecular markers in nephrotic syndrome.
December 1993, American journal of hematology,
M Kazama
Molecular markers of hemostatic activation: future perspectives.
October 1984, Seminars in thrombosis and hemostasis,
M Kazama
[Molecular markers of hemostatic mechanisms--FDP-D Dimer].
March 1989, Rinsho byori. The Japanese journal of clinical pathology,
M Kazama
Changes of hemostatic molecular markers after gynecological surgery.
October 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
M Kazama
[Application of hemostatic molecular markers for diagnosis of thrombosis].
April 2000, Rinsho byori. The Japanese journal of clinical pathology,
M Kazama
Diagnosis of disseminated intravascular coagulation by hemostatic molecular markers.
January 2000, Seminars in thrombosis and hemostasis,
M Kazama
[Molecular markers of hemostatic mechanisms--thrombin-antithrombin III complex].
March 1989, Rinsho byori. The Japanese journal of clinical pathology,
Copied contents to your clipboard!